Now, researchers at Washington University School of Medicine in St. Louis, Missouri have developed a pathbreaking blood test. We believe that this new test can be a game changer for the diagnosis and management of Alzheimer’s disease. This new test employs the biomarker MTBR-tau243 to detect critical proteins associated with the illness. It provides critical information on the disease’s trajectory and level of seriousness.
MTBR-tau243 is a small immuno-modulating fragment of the tau protein. This protein is infamous for its role in the formation of neurofibrillary tangles in the brains of individuals with Alzheimer’s disease. By measuring the levels of this biomarker, healthcare providers can gain a clearer understanding of the stages of Alzheimer’s disease in patients. MTBR-tau243 levels increase markedly in those with Alzheimer’s-related mild cognitive impairment. In those experiencing late-stage symptoms, these levels can increase up to 200 times their normal levels.
The importance of this finding is that a diagnostic test can be made faster and easier. Current diagnostic processes for Alzheimer’s are highly invasive, including PET scans or analyzing cerebrospinal fluid. These approaches can be costly and aren’t easily available to every commuter. The MTBR-tau243 blood test represents a more straightforward choice for assessing the disease. It’s a cheaper option to test for and quantify its prevalence and severity.
Dr. Randall J. Bateman, one of the chief investigators on the study exclaimed, “This novel blood test can reliably confirm the level of tau tangles in the brain. It may be useful for identifying not only the stage of Alzheimer’s disease but if the cognitive decline is due to this disease.” He emphasized that this biomarker allows clinicians to track clinical symptoms more effectively, making it easier to devise appropriate treatment plans.
Additionally, MTBR-tau243 functions not just as a diagnostic tool, but key in assessing disease progression. Greater levels of this biomarker are associated with greater cognitive symptoms of Alzheimer’s. The beauty of this information is it enables physicians to personalize treatment plans based on how the disease is progressing.
Dr. Kanta Horie highlighted an important connection between cognitive decline and tau pathology. According to Brendel, “In AD, cognitive impairment is more closely related to tau NFTs in the brain, and not to amyloid plaques pathology.” This fulfills a critical gap of identifying tau tangles as a core feature in Alzheimer’s for the purpose of research and clinical diagnosis.
The first study was a proof-of-concept and showed promising results, but researchers say more validation is required. Dr. Manisha Parulekar in her preliminary remarks articulated the need to replicate the original study. She argued that larger, more diverse populations are necessary to validate its accuracy and reliability across multiple demographics, ethnicities, and disease progression stages.
Further, she observed that testing must involve people with different neurological conditions to test for specificity. Developing standardized, reproducible protocols for the collection and analysis of blood will be critical to enable comparable results across different health care delivery systems.
Today, Alzheimer’s treatments are few and less effective at later stages of the disease. A dependable blood test, such as MTBR-tau243, will allow for an earlier, more definitive diagnosis. This enables earlier, more effective interventions to reduce or even reverse disease progression. Parulekar explained that, “A blood test provides a much easier and cheaper option. In fact, there’s a widespread recognition that the earlier Alzheimer’s… is diagnosed, the more effective the intervention needs to be.”
As therapeutics continue to progress, anti-amyloid and anti-tau drugs are the first on the frontlines. The introduction of MTBR-tau243 would be a big step toward the future promise of precision medicine for Alzheimer’s disease. Parulekar expressed optimism regarding this potential impact: “We believe that this new biomarker becomes the key to establish the plasma biomarkers panel to stage Alzheimer’s disease.”
Leave a Reply